Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Clinical Study to Investigate the Efficacy and Safety of Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

NCT05400070 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT05400070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05400070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Clinical Study to Investigate the Efficacy and Safety of Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Lead sponsor
Tang-Du Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2021
Completion date
December 30, 2026
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, chemotherapy, lung cancer, sintilimab